Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oral Contraceptive Switch Advocates Reject User Age As Approval Factor

Executive Summary

FDA could soon receive an NDA from non-profit research group Ibis Reproductive Health and HRA Pharma, for an oral contraceptive switch in the US.

Advertisement

Related Content

Oral Contraceptive OTC Proposal Moves Closer With Start Of Actual Use Study
Oral Contraceptive OTC Proposal Moves Closer With Start Of Actual Use Study
OTC Oral Contraceptive Interest Could Be Price Sensitive, Study Suggests
OTC Oral Contraceptive Interest Could Be Price Sensitive, Study Suggests
Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
HHS Plan To Exempt Employers From Birth-Control Mandate Threatens IUD Sales
FDA Drops Access Restrictions On Generic OTC Emergency Contraceptives

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120922

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel